In search of a Kuur: Cell Medica rebrands and regroups, taking a new name, a new CEO and new money
Four years after London-based upstart Cell Medica teamed up with Baylor to work on next-gen cell therapies, the company is doing a complete makeover and adding some new cash to the reserves.
Out goes the name. Cell Medica is now Kuur Therapeutics, which is looking to launch a new Phase I study, matching the first one in the clinic, using their chimeric antigen receptor natural killer T cell (CAR-NKT) therapy platform. Kuur is based in Houston, close to its partners at Baylor.
And out goes the CEO. Experienced biopharma vet Chris Nowers is out less than 2 years after he took the title. He’s being replaced by Kevin Boyle, who had been the CFO at Cell Medica.
IP Group, Baylor College of Medicine and Schroeder Adveq are putting up an unspecified investment to get the clinical work kickstarted. The money will also go to back a preclinical allogeneic CAR-NKT therapy for hepatocellular carcinoma, ahead of an IND submission anticipated in H1 2021.
Social image: Chris Nowers via Business Wire